blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1

This blog is brougt to you consistent with subsection 3 of the Protection from Harassment Act - i.e. blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1



Wednesday, 1 December 2010

Baum Hedlund named as Scientology attorneys


Baum Hedlund named as Scientology attorneys - note CCHR lost against Lilly






Know the Attorneys for Scientology: knowledge is key!



George “Skip” William Murgatroyd III 61y attorney (PTS/SP '88, patron '06) (UT) (Tracey Forbes Murgatroyd 58y (Solo Nots I '97), ex-w: Joy L. Callahan, Jack William Murgatroyd (TR '05), f:George W. Murgatroyd II b:12-4-16 d:3-15-99



CCHR (lost against Eli Lilly pharma. Company)

Coale, Kananak & Murgatroyd

6956 Dume Drive

Malibu, CA 90265-4227 (310) 457-6035 skipmurgatroyd@hotmail.com



Michael Lin Baum 57 years old Clinton, OK, attorney (119511)(D.C.) unindicted co-conspirators (Operation SnowWhite, 'so scientology can have snow white hands' steals federal documents about Hubbard and scientology) (Melissa J. Sirkel Baum 43y)



Baum, Hedlund, Aristei, Schiavo law firm



Paul James Hedlund 63 years old (wife is Marta Louise (Brewer) Hedlund 52y teacher at Rosemont Middle School), ex-wife is Marie Olga (Kiraly) Hedlund 62



J. Clark Aristei

Gary Alan Brown 59 years old (litigant assistant, OSA, Integrity '87)

12100 Wilshire Blvd., Suite 950,

Los Angeles, CA 90025-7106 310-207-3233

Tuesday, 30 November 2010

GLAXO NAMED AND SHAMED IN BOOK SCAM! - but check the details for the bits Fiddaman fails to quote

The book has never been in wide circulation and has not been sold for a few years. Guidelines restricting the use of industry money to support medical journal articles or doctors’ research have come into wide acceptance within the last several years, to try to minimize the influence of companies’ marketing on medical practices.

The book sold about 26,000 copies, including 10,000 bought by SmithKline Beecham for American family doctors and 10,000 purchased by the Dutch pharmaceutical company Organon, Mr. McMillen said. The authors together received a 15 percent royalty of the $120,000 sales, or about $18,000, he said.





Since there are about 100,000 family physicians in the United States, the book reached only a small percentage of them and has probably declined in usage since 1999.



















Drug Maker Wrote Book Under 2 Doctors’ Names, Documents Say


Two prominent authors of a 1999 book teaching family doctors how to treat psychiatric disorders provided acknowledgment in the preface for an “unrestricted educational grant” from a major pharmaceutical company.


http://www.nytimes.com/2010/11/30/business/30drug.html?_r=2&src=busln

Enlarge This Image 



From the book “Recognition and Treatment of Psychiatric Disorders: A Psychopharmacology Handbook for Primary Care.”

Related





A 1997 Letter From Scientific Therapeutics Information (pdf)






But the drug maker, then known as SmithKline Beecham, actually had much more involvement than the book described, newly disclosed documents show. The grant paid for a writing company to develop the outline and text for the two named authors, the documents show, and then the writing company said it planned to show three drafts directly to the pharmaceutical company for comments and “sign-off” and page proofs for “final approval.”



“That doesn’t sound unrestricted to me,” Dr. Bernard Lo, a medical ethicist and chairman of an Institute of Medicine group that wrote a 2009 report on conflicts of interest, said after reviewing the documents. “That sounds like they have ultimate control.”



The 269-page book, “Recognition and Treatment of Psychiatric Disorders: A Psychopharmacology Handbook for Primary Care,” is so far the first book among publications, namely medical journal articles, that have been criticized in recent years for hidden drug industry influence, colloquially known as ghostwriting.



“To ghostwrite an entire textbook is a new level of chutzpah,” said Dr. David A. Kessler, former commissioner of the Food and Drug Administration, after reviewing the documents. “I’ve never heard of that before. It takes your breath away.”



The book has never been in wide circulation and has not been sold for a few years. Guidelines restricting the use of industry money to support medical journal articles or doctors’ research have come into wide acceptance within the last several years, to try to minimize the influence of companies’ marketing on medical practices.



The book’s listed co-authors were Dr. Charles B. Nemeroff, chairman of psychiatry at the University of Miami medical school since 2009 and Emory University before that, and Dr. Alan F. Schatzberg, who was chairman of psychiatry at the Stanford University School of Medicine from 1991 until last year.



The letter documenting the relationship between Dr. Nemeroff, a writing company and SmithKline was dated Feb. 4, 1997. It and a “preliminary draft” of the book, dated Feb. 21, 1997, and adding Dr. Schatzberg’s name were released Monday by the Project on Government Oversight, a Washington advocacy group. They were attached to a letter of complaint to Dr. Francis S. Collins, director of the National Institutes of Health. In the letter, Danielle Brian, executive director of the project, and Paul Thacker, an investigator, formerly with the staff of Senator Charles Grassley of Iowa, also cited other examples of what they termed ghostwriting and asked the N.I.H. for better policing of such practices.



The documents were separately obtained by The New York Times from the Los Angeles law firm of Baum Hedlund, which received them as part of discovery in lawsuits against the drug company, now known as GlaxoSmithKline, involving Paxil. Leemon B. McHenry, a bioethicist with California State University, Northridge, who consults for the law firm, said many similar documents remain sealed. “This is only the tip of the iceberg,” he said.



Responding to questions by e-mail last week, Dr. Nemeroff and Dr. Schatzberg emphasized the “unrestricted” nature of the grant from the drug maker to develop the book and said they did most of the work. SmithKline “had no involvement in content,” Dr. Schatzberg said, adding, “An unrestricted grant does not give the company any right of sign-off on content and in fact they had no sign-off in content.”



Dr. Nemeroff said he and Dr. Schatzberg “conceptualized this book, wrote the original outline and worked on all of the content.”



But the writing company, Scientific Therapeutics Information of Springfield, N.J., had developed “a complete content outline” for Dr. Nemeroff’s comment, according to the 1997 letter from one of the company’s officials. The company also said it had “begun development of the text.” The writing company did not respond to requests for comment.



Kevin G. Colgan, a spokesman for GlaxoSmithKline, said the company’s role in the book was described in its preface. In recent years, he added, the company has tightened its internal guidelines for medical writers.



Ron McMillen, chief executive of American Psychiatric Publishing, which published the book, said he reviewed files on it Monday and found no evidence of influence by the writing company or GlaxoSmithKline. But Mr. McMillen also said he had been unaware of the plan outlined in the two-page letter to Dr. Nemeroff.



“This would show more involvement than we would accept,” he said after reviewing it.



The book sold about 26,000 copies, including 10,000 bought by SmithKline Beecham for American family doctors and 10,000 purchased by the Dutch pharmaceutical company Organon, Mr. McMillen said. The authors together received a 15 percent royalty of the $120,000 sales, or about $18,000, he said.



Since there are about 100,000 family physicians in the United States, the book reached only a small percentage of them and has probably declined in usage since 1999. Dr. Howard A. Brody, an author, blogger and professor of family medicine at the University of Texas Medical Branch at Galveston, speculated that family doctors may have had some resistance to a book from a psychiatric press.



Mr. McMillen said the book was co-published with the American Medical Association. He said it was distributed until a few years ago.



Dr. Nemeroff said the book was written to fill an unmet need in educating family doctors and primary care physicians on how to provide adequate treatment for people with mental illness. “Remarkably, the book remains quite accurate and relevant to clinical practice today,” he said.



Dr. Nemeroff said he and Dr. Schatzberg “scrutinized every page and rewrote and edited as we deemed necessary,” keeping control of the final draft.



Dr. Schatzberg said he had not seen the 1997 letter to Dr. Nemeroff. He termed it “a theoretical proposal that bears little, if any relationship to what actually happened.”



Dr. Lo, who is a professor of medicine and director of the medical ethics program at the University of California, San Francisco, said that medical textbooks and handbooks should make it clear — as peer-reviewed journals now do — whose idea it was, who wrote the first draft, and who edited. Dr. Lo and other experts said ghostwriting has receded in recent years with tougher journal standards.



Dr. Nemeroff and Dr. Schatzberg have been listed on other titles, including co-editors of the Textbook of Psychopharmacology, a book for psychiatrists and medical students, whose third edition appeared in 2003. In 2008, Emory University imposed a two-year ban on Dr. Nemeroff receiving N.I.H. grants after a Senate inquiry found that he had failed to disclose at least $1.2 million in industry financing over seven years from pharmaceutical companies, including GlaxoSmithKline.



Monday, 29 November 2010

Epilim case shows the flaws in the legal aid regime

Epilim case shows the flaws in the legal aid regime

http://www.guardian.co.uk/law/2010/nov/29/epilim-legal-aid-flaws

Families who claim the epilepsy drug was linked to birth defects have few options left after the LSC withdrew funding






Share Comments (10)

Jon Robins guardian.co.uk, Monday 29 November 2010 13.40 GMT Article history

Epilim, the anti-epilepsy drug. Photograph: Zak Waters/Alamy



Earlier this month a legal action involving 100 families seeking compensation for their children collapsed within weeks of the court hearing after a six-year fight. The families in question are suing over a range of claims for birth defects such as spina bifida, heart damage, cleft palates, deformed hands and feet – some claims are in the region of £6m – which they argue are the result of the children's mothers having taken an anti-epilepsy drug when pregnant.



The Legal Services Commission (LSC), which runs the legal aid scheme in England and Wales, says of its decision to withdraw funding that it "can only spend taxpayers' money where we believe there is a reasonable prospect of success". Taxpayers can make up their own minds as to whether spending £3.25m over the past six years supporting the litigation only to pull the plug within weeks of the case going to court represents good value for money.



I spoke to Emma Friedman, mother of 12-year-old Andy, this week. She took Epilim, manufactured by Sanofi-Aventis, when pregnant to prevent epileptic fits. "Andy is 12 years old now with a mental age of a three year old," she tells me. Her son is at secondary school in a special autistic unit and will need life-long care.



What does Emma make of the LSC's decision to pull the plug? "This sounds cold. But after paying £3.25m so far it doesn't even make good business sense to quit before the taxpayer gets the opportunity for a return on their investment. The taxpayer will pay for my son until the day he dies." She worries this is her son's last chance for justice because of the limitation bar on bringing cases. So where do the families go now? They are looking at judicially reviewing the LSC's decision. But as Emma puts it: "I feel intimidated by the prospect of challenging the LSC, government and the fourth largest drug company in the world."



Sir Menzies Campbell MP, the former Liberal Democrat leader, recently accused the LSC of playing "judge and jury". It's a good point. We are seeing brutal cuts to legal aid – £325m out of £2.1bn. One reason why the LSC was created separate from government was to allow it to make funding decisions without the accusation of being treasury-led or politically-driven. Now the LSC is about to be flung on to the quango bonfire, and its role subsumed into the Ministry of Justice.



Suing a drug company in the UK courts for a case such as Epilim appears to be nigh on impossible. It joins a truly dismal roll call of failed group actions: the 2002 oral contraception pill litigation (fell apart following 44 days of legal argument), the MMR litigation (collapsed in 2003 having cost £15m), and the notorious benzodiazepine tranquilliser cases, which swallowed up £30m of taxpayers' money without even seeing the inside of a courtroom.



It is this "bitter experience" – the LSC's words – that led to the funding regime we now have: there is only £3m available a year for major multiparty actions and any litigation is subject to an annual affordability review.



Increasingly, legal aid isn't there for such complex cases. The expectation from this month's green paper on legal aid is that the private sector steps in and lawyers run these cases on "no win, no fee" backed by after-the-event insurance. The reality is that insurers don't back families fighting multinational drug companies.



Consider the plight of the Vioxx litigants. In November 2007 the manufacturer Merck paid more than $4.85bn to Americans who claim to have suffered heart attacks and strokes as a result of the anti-arthritis drug. By contrast, the UK legal action never really got off the ground. The claimants couldn't get legal aid nor could they find an insurer to back their case. They were left taking their cases to New Jersey where the judge ruled against them on the grounds that their home country had "a perfectly appropriate judicial system". The problem is they could not get their case into court at all.



David Body, the partner at Irwin Mitchell representing the Epilim families, is sceptical about the prospects of funding the case privately. "It's late in the day and there is likely to be an enormous insurance premium to deal with the potential cost for a trial against a multinational drugs company." And as he puts it: "That is why legal aid is there. It is designed to enable people of modest means to get through the courtroom door." Quite; the problem is it's not working.



Jon Robins is a freelance journalist and director of the research company Jures

Sunday, 28 November 2010

wikileaks El Pais, Le Monde, Speigel, Guardian & NYT will publish many US embassy cables tonight

wikileaks El Pais, Le Monde, Speigel, Guardian & NYT will publish many US embassy cables tonight, even if WikiLeaks goes down


about 1 hour ago via web

Retweeted by you and 100+ others

http://twitter.com/wikileaks

Wikileaks 'hacked ahead of secret US document release'

Wikileaks 'hacked ahead of secret US document release'


Wikileaks has previously released documents relating to Iraq and Afghanistan

Continue reading the main story http://www.bbc.co.uk/news/world-us-canada-11858637?utm_source=twitterfeed&utm_medium=twitter

Wikileaks War Files

Tidal wave of secret files raises new questions

Key issues in Iraq documents release

Excerpts: Iraq war logs

Pressure for openness

Whistle-blowing website Wikileaks says it is under attack from a computer-hacking operation, ahead of a release of secret US documents.



"We are currently under a mass distributed denial of service attack," it says on its Twitter feed.



It adds that several newspapers will go ahead and publish the documents released to them by Wikileaks even if the site goes down.



The US state department has said the release will put many lives at risk.



Wikileaks founder Julian Assange has said the US authorities are afraid of being held to account.



Wikileaks has said the release of classified messages sent by US embassies will be bigger than past releases on Afghanistan and Iraq.



The newspapers set to publish details of the US embassy cables include Spain's El Pais, France's Le Monde, Germany's Speigel, the UK's Guardian and the New York Times.



The latest leak is expected to include documents covering US dealings and diplomats' confidential views of countries including Australia, Britain, Canada, Israel, Russia and Turkey.

"The material that we are about to release covers essentially every major issue in every country in the world," Mr Assange told reporters by video link on Sunday.



A journalist with Britain's Guardian newspaper, which has been working with Wikileaks on publishing the files, said they would include an unflattering US assessment of UK PM David Cameron.



No-one has been charged with passing the diplomatic files to the website but suspicion has fallen on US Army private Bradley Manning, an intelligence analyst arrested in Iraq in June and charged over an earlier leak of classified US documents to Mr Assange's organisation. "

Scientology cult contract - From Wikileaks

Scientology cult contract


From Wikileaks    http://web.archive.org/web/20101128123214/http://https:/secure.wikileaks.org/wiki/Scientology_cult_contract


•scientology-staff-contract.pdf (click to view full file)


•scientology-staff-contract.pdf (alternative address)

Analysis

No analysis or reportage yet. Please carefully read this document and submit your findings.

Summary



Scientology "enrollment application, agreement and general release" form (section 1).", which according to document time stamps was scanned in from paper form on Sat Apr 26 11:08:04 2008.



Anyone who wishes to attend or participate in one of Scientology's religious services MUST sign this document before they can do so. Section two of the contract effectively defines everything Scientology does as a "religious service".



Those who wish to attend or participate in one of Scientology's "religious services" must sign this document before they can do so. Section two of the contract effectively defines everything Scientology does as a "religious service".



By signing the contract a person agrees that any and all disputes they have with Scientology and its affiliates that cannot be resolved informally will be handled by an internal arbitration system. Under no circumstances will they or anyone acting on their behalf take any sort of legal action against the Church/affliliates/employees. If they (or someone acting on their behalf) does try to take legal action, this contract will be presented as sufficient evidence for having the case dismissed immediately and with prejudice.



By signing this contract a person is also stating that they fully agree with Scientology's opposition to Psychiatry and that they themselves absolutely do not want to be committed to Psychiatric care.



The document's primary effect appears to prevent members of Scientology from suing the Scientology for any abuses, negligence or to regain donated moneys or course fees.

Context

United States

Church or religious organization

Scientology

Wikileaks release date



Sunday April 27, 2008

Primary language



English

File size in bytes



4747281

File type information



PDF document, version 1.6

Cryptographic identity



SHA256 7e34adf08dc0908a50cb8652179af25135eef01f6e969b388c1c5d0dabb725fa

Description (as provided by the original submitter)



This is the Staff Contract all non-Sea Org staff members are required to sign before ANYTHING.



1. Possible partial excerpts, not aware of entire document being released.



2. It demonstrates the control it exerts on its members, and it's hostility to mental health practitioners.



3. Anyone with an interest in the subject.



4. Any ex-member could verify, as well as via the Religious Technology Center (http://web.archive.org/web/20080508162657/http://www.rtc.org/contacts.html)



5. To help increase understanding of what joining the cult entails.

Saturday, 27 November 2010

WILILEAKS - D notice revealed

From: Andrew Vallance


Sent: Fri 26/11/2010 12:42



To: Sunday Telegraph; Ian Martin; Sunday Telegraph; Channel Five; Caroline Wyatt; C4 News Desk; Sun; Kevin Brown; Sunday Mail; Mail on Sunday; Five TV; Associated Press TV; William Lewis; Tim Marshall; Press Gazette; Allister Heath; Jonathan Collett; Daily Telegraph; Daily Record; Evening Standard; Daily Star; Independent on Sunday; Observer; Foresight News; Daily Express; Sunday Times; Financial Times; Associated Press; Times; Spark FM; chris wissun; Sunday Mirror; Sunday Herald; News of the World; Tom Newton-Dunn; Stephen Abell; Scotsman; Press Association; BFBS Will Inglis; Will Gore; Mark Birdsall; Guardian; Daily Mail; Daily Mirror; People; Foresight News; Telegraph Legal; Glenmore Trenear-Harvey; Sunday Post; Reuters; ITV News Desk; Independent; Evening Times; Jonathan Grun; Glasgow Herald; Five TV



Subject: DA Notice Letter of Advice to All UK Editors – Further Wikileaks Disclosures



To All Editors



Impending Further National Security Disclosures by Wikileaks



I understand that Wikileaks will very shortly release a further mass of US official documents onto its internet website. The full scope of the subject matter covered by these documents remains to be seen, but it is possible that some of them may contain information that falls within the UK’s Defence Advisory Notice code. Given the large number of documents thought to be involved, it is unlikely that sensitive UK national security information within these documents would be recognised by a casual browser. However, aspects of national security might be put at risk if a major UK media news outlet brought such information into obvious public prominence through its general publication or broadcast.



Therefore, may I ask you to seek my advice before publishing or broadcasting any information drawn from these latest Wikileaks’ disclosures which might be covered by the five standing DA Notices. In particular, would you carefully consider information that might be judged to fall within the terms of DA Notice 1 (UK Military Operations, Plans and Capabilities) and DA Notice 5 (UK Intelligence Services and Special Forces). May I also ask you to bear in mind the potential consequential effects of disclosing information which would put at risk the safety and security of Britons working or living in volatile regions where such publicity might trigger violent local reactions, for example Iran, Iraq, Pakistan and Afghanistan?



As always, I am available 24/7 to offer DA Notice guidance…



Yours Sincerely,



Andrew Vallance



Air Vice-Marshal

Secretary, Defence Press and Broadcasting Advisory Committee

WIKILEAKS - Citizens Commission on Human Rights exposed as a Scientology front

Citizens Commission on Human Rights exposed as a Scientology front - wikileaks


Release date



http://sunshinepress.org/wiki/Citizens_Commission_on_Human_Rights_exposed_as_a_Scientology_front





March 7, 2008







Note







Wikileaks has made public the submission, since the material is no longer available at the link described earlier today.



Download 



http://file.wikileaks.org/file/cchr-mails.zip



File

Torrent

Magnet



Further information







Context



United States



Non-governmental organization



Citizens Commission on Human Rights



Primary language







English



File size in bytes







282977



File type information







Zip archive data, at least v1.0 to extract



Cryptographic identity







SHA256 bcf6936c8d2d4865d1802b334934e4bb72db7b7b2d2a32b494d1a0d0c9473895



Description (as provided by our source)







1. Download link just released into the chat forums at: http://forums.enturbulation.org/viewtopic.php?f=12&t=6059







2. The file contains e-mails between members of CCHR (an anti-psychiatry front group of the Church of Scientology)







3. Likely audience: anyone seeking psychological care for themselves or a loved one.







4. Visit the forum via the link above to join in the discussion of these leaked e-mails, and view the original post by the individual who leaked them. You may private message the individual there.







5. It was leaked for a number of reasons:







- Scientology denies that it is behind CCHR (which is clearly contradicted by the references in the emails)







- It shows, clearly, how Scientologists and the CCHR are deliberately manipulating the media... using false accounts and sock puppetry to skew information.







- It shows just how Machiavellian and hypocritical the CCHR is in their planning and execution of attacks against peer-reviewed medical science.







6. Yes. The CCHR's campaign of misinformation is designed specifically to derail people seeking psychiatric help, and instead funnel them toward Scientology. This nonsense, and lack of peer-reviewed treatment CCHR recommends instead (vitamins, niacin, hot saunas) is likely to harm rather than hel

WIKILEAKS - on twitter - UK Government has issued a "D-notice" warning to all UK news editors

http://twitter.com/wikileaks


. The D-notice is type 1 and type 5.


7:43 PM Nov 26th via web

Reply Retweet . UK Government has issued a "D-notice" warning to all UK news editors, asking to be briefed on upcoming WikiLeaks stories

WIKILEAKS - what America REALLY thinks of its friends .....???

U.S. warns world leaders that new WikiLeaks revelations will 'expose corruption between allies' and show what America REALLY thinks of its friends


By Daily Mail Reporter

Last updated at 5:27 PM on 27th November 2010   

3 million documents set to go online

U.S. diplomats face being kicked out of countries in backlash

Corrupt politicians expected to be named and shamed

Bombshell leak thought to include U.S. assessments of Gordon Brown

Secret talks on return of Lockerbie bomber to Libya may also be leaked

Allegations 'include U.S. backing of Kurdish terrorists'

Blowing the whistle: Julian Assange, the founder of WikiLeaks (pictured earlier this month), is said to be preparing to release more sensitive documents

World leaders were warned last night by America that damaging secrets about their nations were about to be laid bare.

The documents include highly damaging and embarrassing communiques from U.S. embassies around the world, especially from London - revealing the truth behind the so-called 'special relationship' between the U.K. and the U.S.

The U.S. ambassador to London made an unprecedented personal visit to Downing Street to warn that whistleblower website WikiLeaks was about to publish secret assessments of what Washington really thinks of Britain.


The website is on the verge of revealing almost three million documents, including thousands of sensitive diplomatic cables sent to Washington from the American embassy in London.


The bombshell leak is thought to include U.S. assessments of former British prime minister Gordon Browns personality and his prospects of winning the General Election, and secret discussions on the return of the Lockerbie bomber to Libya.


Assessments of current Prime Minister David Camerons election chances and his private assurances to U.S. officials may also be included, Government sources believe.


They fear they will emerge on Sunday in co-ordinated releases in newspapers in Britain, Germany and America.

The British government is so worried that last night it issued a D-Notice, warning that publishing the secrets could compromise national security.

The website has previously released secret details of allied military operations in Iraq and Afghanistan.

Revelations of American brutality in Iraq and Afghanistan created shockwaves, made WikiLeaks notorious and led to its founder Julian Assange - an Australian-born computer hacker - being vilified by governments around the world. He is now wanted for alleged rape in Sweden.

In total, around 2.7million confidential messages between the U.S. government and its embassies around the world are to be released.


Read more: http://www.dailymail.co.uk/news/article-1333532/WikiLeaks-revelations-expose-corruption-allies-U-S-warns.html#ixzz16Vi7rrIV

Tuesday, 23 November 2010

GSK countersue seroxatUSERSgroup ???

The Tightening of the Screw - UK Litigation.





Litigation sees David go up against Goliath.



Goliath are currently turning the screw on the David's - money being their ammunition.




Q: What can you gain by trying to get blood out of a stone? Fear, insecurity, confusion?

And they really think this won't go public.



Trust me, it will.    




Fiddly

Dr Douglass Condemns GSK - snake oil salesman


Dr Douglass Condemns GSK


Bad batch proves shots not safe




Let’s stop pretending: There’s no way in hog heaven these swine flu vaccines are safe.


Need more proof? Look north – at least one Canadian is dead and dozens of others are recovering from severe allergic reactions to the vaccine.






Many of those cases were linked to GlaxoSmithKline’s Arepanrix swine flu vaccine, which prompted a recall of 172,000 doses. But by the time word got out, all but 15,000 had been used.


If you already rolled up your sleeve in Canada – too bad. Just be glad you’re still alive to read about it............. zzzzzzzzzzzzzzzzzzzzzzzz zzzzzzzzzzzzzzzzz zzzzzzzz
 
read on

Dr Douglass Condemns GSK

see also  

http://www.realadvantagenutrients.com/


Ultra Turbo HG


Get rock solid results for as long as you want

Forget the letdowns and embarrassment

Monday, 22 November 2010

Drugs licensing flaws exposed - By Sarah Boseley posted 6 October 04

Drugs licensing flaws exposed


http://nswcnna.blogspot.com/2004/10/drugs-licensing-flaws-exposed.html


Special report: Pfizer advised on how to get antidepressant approved by member of body deciding on application.



A leading figure in the world of psychiatry gave a pharmaceutical company advice on how to get its new drug approved while he was sitting on the committee which was deciding the licence application.



An internal memorandum from Pfizer, the world's largest drug company, says Stuart Montgomery would be happy to become a paid adviser and declare an interest to the Committee on the Safety of Medicines (CSM) once the drug, an antidepressant to rival Prozac, had been through the licensing process.



The drug, sertraline, which acquired the brand name Lustral, became a billion-dollar success, but is now one of several banned from use in children in the UK because of evidence they can cause them to become suicidal. Their use in adults is under investigation.



Dr Montgomery says his ad vice to Pfizer in 1989 was permissible because he was not receiving money from the company at the time. But Kent Woods, chief executive of the drug regulatory body which grants licences on the advice of the CSM, said such conduct was "absolutely unacceptable".



"Not only does each member [of the CSM] on appointment sign a letter ensuring confidentiality but at every meeting, the chair as a matter of routine reminds everybody that proceedings are confidential," he said. If the company had questions, they should have talked to officials of the Medicines and Healthcare products Regulatory Agency (MHRA), not the independent CSM experts.



Critics say the case exposes weaknesses in the drug licensing system, run by a regulatory body which, other papers obtained reveal, it has an unquestioning relationship with drug companies.



That relationship is so close that the pharmaceutical trade body in June drew up a business plan for the regulator, concluding: "Our priorities are aligned."



In the first of a two-part investigation into the influence of the drug companies over doctors and government intimacy between the industry and the regulator.



The MHRA is responsible for licensing medicines and regulating the industry. It relies on the advice of the independent experts on the CSM when it grants a new product licence. These experts, from all fields of medicine, are supposed to declare any pharmaceutical company interests, such as consultancies, fees and shareholdings, and must leave the room when drugs from companies that have paid them are discussed.



During his time on the CSM, Dr Montgomery disclosed payments for lectures and advice from Eli Lilly, the makers of Prozac, and from Organon, Beecham, Merck, Sanofi, Glaxo, Novo, Jouveinal, Duphar, Wyeth and Almirall.



Dr Montgomery, who held a joint post with St Mary's hospital, Paddington, and Imperial College in London, was a psychiatric expert on the CSM. His opinion was crucial in 1989, when the Medicines Control Agency as it was then known was considering an application from Pfizer for a licence for sertraline.



A confidential internal memorandum from Pfizer, dated April 24 1989, which was submitted in evidence to a recent court case in the US, has together with Mind, the national association for mental health, which has been campaigning for better drug regulation. Richard Brook, its chief executive, will today call for an external inquiry. "There is clear confusion about the role that Dr Montgomery was playing in this situation," he said.



"It also makes it very difficult for outsiders to believe there was not a serious conflict of interest when one of the major experts on depression involved in the CSM is actually speaking to a drug company about how they best present their results for licencing."



Dr Montgomery became a professor of psychiatry at Imperial College in 1993. The journal he edits, International Psychopharmacology, regularly publishes company-funded studies of antidepressants, as other journals do. He authors many of the papers, often jointly with other senior figures in the field.



The memo reveals that Dr Montgomery met Pfizer officials at St Mary's. He told them the committee had accepted that the drug was effective but "the safety analyses require re-presentation" and he advised them how to go about it.



He told Pfizer they must appeal against the CSM's initial decision. The memo reveals that Dr Montgomery is not going to declare an interest in Pfizer.



"He would still like to remain a disinterested party at the CSM till the appeal was heard," says the memo. "Thereafter he would be happy to act as an adviser to Pfizer and declare an interest."



The Pfizer drug got its approval first in the UK. Other European regulators were not happy that the data from clinical trials proved it worked.



Dr Montgomery said he had no conflict of interest over Pfizer. "My comments to Pfizer in 1989 were the usual clarification of the objections of the CSM to their application. At that time I had no conflict of interest with Pfizer, I was not a paid consultant, I was not in receipt of research grants from Pfizer, and I did not own shares in Pfizer," he said.



"The extracts from the memorandum make it clear that I was a disinterested party and was not prepared to consider a relationship with Pfizer while an application was under review."



By Sarah Boseley posted 6 October 04

Friday, 19 November 2010

AVANDIA informed consent - if u don't like it, don't take it !

AVANDIA informed consent - if u don't like it, don't take it !



http://health.groups.yahoo.com/group/criticalpsychiatry/message/64675




http://www.fileden.com/files/2008/5/6/1899375//Avandia%20-%20HC%20Nov%2018-2010.pdf



AVANDIA® /AVANDAMET®/AVANDARYL® Patient Informed Consent -4- My doctor has recommended one of the following medicines to treat my diabetes (please check one of the boxes below, as appropriate):



â–¡ AVANDIA® â–¡ AVANDAMET® â–¡ AVANDARYL®



Please read this Patient Informed Consent ("Consent") and the individual Consumer Information for AVANDIA®/AVANDAMET®/AVANDARYL® and discuss any questions or concerns with your doctor before you sign this Consent.



Do not sign this Consent and do not take AVANDIA®/AVANDAMET®/AVANDARYL® if there is anything you do not understand about the information you have received.



I am aware that:



AVANDIA®/AVANDAMET®/AVANDARYL® are medicines used in addition to diet and exercise to lower blood sugar in people with type 2 diabetes when all other diabetes medicines taken orally (by mouth), either alone or in combinations, have not lowered blood sugar enough or are not appropriate.



Rosiglitazone, the active ingredient in AVANDIA® and one of the active ingredients in AVANDAMET® and AVANDARYL®, may increase the risk of serious heart problems, including:



• heart failure



• angina (chest pain)



• heart attack (myocardial infarction)



• fluid retention (with or without weight gain)



AVANDIA®/AVANDAMET®/AVANDARYL® should not be used if I have or have had heart problems.



There are other options to treat my diabetes, as explained by my doctor.



There are other risks associated with AVANDIA®/AVANDAMET®/AVANDARYL® that are outlined in the individual Consumer Information for AVANDIA®/ AVANDAMET®/AVANDARYL® and I have been given the opportunity to ask and discuss any questions or concerns about those risks with my doctor.



I understand that in order to be prescribed AVANDIA®/AVANDAMET®/ AVANDARYL®, I am required to sign this Consent.



AVANDIA® /AVANDAMET®/AVANDARYL® Patient Informed Consent -5- My doctor has explained the above to me, I have been given time to read this Consent and the individual Consumer Information for AVANDIA®/AVANDAMET®/AVANDARYL® carefully, and to discuss it with my doctor. I now authorize my doctor to continue/begin my treatment with AVANDIA®/AVANDAMET®/AVANDARYL®.



Patient or Legally Appointed Guardian signature lines are below. AVANDIA®/ AVANDAMET®/AVANDARYL® are not recommended for use in people under the age of 18.



Patient (and Legally Appointed Guardian if applicable) Name(s)



Please Print:________________________________________________________________



Patient / Legally Appointed Guardian Signature:



______________________________________________________________________________



Date _________________________

Wednesday, 17 November 2010

Jon Medland - video - APRIL interview "forgets to mention" the Cipramil, why?


A father talks about his medical student son's suicide and the acne treatment Roaccutane from APRIL on Vimeo.


Jon's father, Jonathon Medland Snr, is interviewed by founder of the APRIL charity, Millie Kleve. APRIL stands for Adverse Psychiatric Reactions Information Link ......yet he starngely fails to point out that Jon junior was also taking Cipramil !

Jon Medland - Cipramil (citalopram) suicide ? .... Guardian Oct 2004

The inquest heard that the following day he returned to Manchester where his flatmates noticed that he was uncharacteristically quiet. He began acting strangely and told them he had been experiencing suicidal thoughts.



http://www.guardian.co.uk/society/2004/oct/20/health.medicineandhealth  




Though Mr Medland had been due to see Dr Muston for a follow-up appointment that week, his flatmates urged him to see his GP, which he did on January 12, and was prescribed the anti-depressant Citalopram. The following day, Mr Medland's flatmate found him dead in his room

Tuesday, 16 November 2010

Roaccutane - Jon Medland medical student who knew the risks ?

Medical student's suicide after taking acne drugCoroner calls for 'clear warnings' on skin remedy


http://www.guardian.co.uk/society/2004/oct/20/health.medicineandhealth

Share Laura Barton The Guardian, Wednesday 20 October 2004 02.11 BST Article historyA promising medical student killed himself four weeks after being prescribed a controversial acne drug, an inquest in Manchester heard yesterday.



Jon Medland, 22, was in the final year of his medical degree at Manchester University when  he hanged himself at his student lodgings early on January 13 this year.



Leonard Gorodkin, the Manchester coroner, was told that in a short time Mr Medland had been transformed from a "bubbly, outgoing" young man with a love of student life and Manchester United to becoming withdrawn and depressed with suicidal thoughts. Mr Medland had suffered from mild acne for several years, but the inquest heard that he had become self-conscious about dealing with patients.



By last autumn he had tried three different types of antibiotic and various topical treatments, and although he had noticed some improvement in his skin, the acne had not cleared.



Through his own research, Mr Medland had learned of the drug Roaccutane, used to treat more severe cases of acne. Mr Medland was referred by his GP to Dr Haydn Muston, consultant dermatologist at Withington Hospital, Manchester, and attended his first appointment on December 11.



Dr Muston told Mr Gorodkin that it was not standard practice to prescribe treatment at the initial appointment, but as Mr Medland was a medical student and had already researched the possible side-effects of the drug, he wrote him a prescription that day. "I felt Jon wanted to get started," he said.



Mr Medland went home to Devon for Christmas, where his family and his girlfriend noticed nothing unusual about his behaviour, the hearing was told. It was only once he had begun a placement at a medical practice in Shrewsbury on January 5 he began to complain of feeling tired and stressed, and had doubts about his academic abilities.




He told friends and family that he feared his mental state was somehow connected to the Roaccutane, and that he had "read somewhere" that the effects might not cease when he stopped taking the drug. They told him to stop taking the Roaccutane tablets, which he did on January 8.



The inquest heard that the following day he returned to Manchester where his flatmates noticed that he was uncharacteristically quiet. He began acting strangely and told them he had been experiencing suicidal thoughts.



Though Mr Medland had been due to see Dr Muston for a follow-up appointment that week, his flatmates urged him to see his GP, which he did on January 12, and was prescribed the anti-depressant Citalopram. The following day, Mr Medland's flatmate found him dead in his room.



Recording a verdict that Mr Medley killed himself, Mr Gorodkin said: "For a drug to affect a person of a very solid life foundation, if it can lead them to take their own life, then it deserves further investigation, if a link can be proved.



"But I cannot say with any certainty that the effects of the drug Roaccutane led him to take his own life. All I can say is that the warnings that are already present should be made very clearly and strongly."



Earlier this year, European medicine watchdogs announced a review of Roaccutane's safety record, following concern regarding alleged links to suicide and depression.



The drug's manufacturer, Roche, says that 13 million people worldwide have used Roaccutane, and although it is not possible to say how many of these are in Britain, by last January an estimated 375,000 treatment courses may have been prescribed.

Sunday, 14 November 2010

will claim compensation for the use of the drug as well as the cost for them to safely come off the drug

Lawyers representing the UK Seroxat Users Group are planning to launch a multi-million pound lawsuit against GSK next month. The 3,500 members of the group allege that the antidepressant is a defective product under the Consumer Protection Act. The members say that they experienced dependency/withdrawal symptoms and will claim compensation for the use of the drug as well as the cost for them to safely come off the drug

http://webcache.googleusercontent.com/search?q=cache:4ZNzX-vz7JUJ:www.youclaim.co.uk/Personal_Injury_News.asp%3Fspid%3D143+seroxat+legal+aid+3500&cd=1&hl=en&ct=clnk&gl=uk


http://www.youclaim.co.uk/Personal_Injury_News.asp?spid=143